RC48 Combined With Tislelizumab

Phase 2Monoclonal antibody

RC48 Combined With Tislelizumab is one of 15 small molecule programs targeting Tislelizumab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TislelizumabRecruiting

TislelizumabPhase 2

Recruiting

Competition

Competitive Landscape

15 competitors in Tislelizumab

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 2

15 2

Mekinist

Novartis

Phase 2

1 3

Eloxatin

Teva

Phase 2

1 4

Taxol

Teva

Phase 2

1 5

Camptosar

Pfizer

Phase 2

1 6

LUNSUMIO

Roche

Phase 2

1 7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Phase 2

1 8

Gemzar

Johnson & Johnson

Phase 1

1 9

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Tislelizumab

NCT05912816

Clinical

Trials by Indication[1]

Tislelizumab1 trial

Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Recruiting·RRenJi Hospital·Phase 2·NCT05912816·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RC48 Combined With Tislelizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RC48 Combined With Tislelizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RC48 Combined With Tislelizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RenJi Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: RRenJi Hospital

RC48 Combined With Tislelizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Tislelizumab1 trial

References

Drug Info

Quick Facts

Related News